![whitehouse-157289724](/-/media/images/caregiver-news/physicians-apcs/whitehouse-157289724.jpg?la=en&h=597&w=896&mw=896&hash=709269B04B546DC53C2772B0014077697992EF24)
The National Institutes of Health (NIH) recently formed a COVID-19 Treatment
Guidelines Panel to provide information to healthcare practitioners and the public across the U.S. about treatment for patients with COVID-19. Andrew Pavia, MD, pediatric infectious disease specialist who oversees pediatric infectious disease at Primary Children’s Hospital, and the U of U Health’s Chief for the Division of Pediatric Infectious Diseases, was recently appointed to this panel. The panel includes 30 experts, including Dr. Pavia, drawn from U.S. healthcare and academic organizations, federal agencies, and professional societies. It’s co-chaired by Roy Gulick, MD, Chief of the Infectious Disease Division at Weill Medical Hospital of Cornell University in NYC; H. Clifford Lane, MD, Clinical Director of the National Institute of Allergy and Infectious Diseases, NIH; and Henry Masur, MD, Chief of the Critical Care Medicine Department at the NIH Clinical Center.
Members of the guidelines panel, appointed by the co-chairs, were chosen based on their clinical experience and expertise in patient management, translational and clinical science, and/or the development of treatment guidelines. Dr. Pavia was personally notified by Anthony Fauci, MD, the Director for the National Institute of Allergy and Infectious Diseases who’s been one of the key leaders to the White House Coronavirus Task Force.
Dr. Pavia has been involved in research on antiviral agents for three decades. He has been a member or chair of several advisory committees and subcommittees for the U.S. government dealing with pandemic preparedness, biodefense, and vaccine policy including the CDC Board of Scientific Counselors, the National Vaccine Advisory Committee, and the National Biodefense Science Board. He is the Co-Chair of the IDSA Guidelines Committee for the treatment of influenza.
Congratulations to Dr. Pavia for this honorable recognition and for his willingness to guide treatment for COVID-19 patients here in Utah and across the country. The guidelines are posted online (covid19treatmentguidelines.nih.gov) and will be updated often.
![anthony pavia](/-/media/images/caregiver-news/physicians-apcs/anthony-pavia.jpg?h=224&w=160&la=en)
Members of the guidelines panel, appointed by the co-chairs, were chosen based on their clinical experience and expertise in patient management, translational and clinical science, and/or the development of treatment guidelines. Dr. Pavia was personally notified by Anthony Fauci, MD, the Director for the National Institute of Allergy and Infectious Diseases who’s been one of the key leaders to the White House Coronavirus Task Force.
Dr. Pavia has been involved in research on antiviral agents for three decades. He has been a member or chair of several advisory committees and subcommittees for the U.S. government dealing with pandemic preparedness, biodefense, and vaccine policy including the CDC Board of Scientific Counselors, the National Vaccine Advisory Committee, and the National Biodefense Science Board. He is the Co-Chair of the IDSA Guidelines Committee for the treatment of influenza.
Congratulations to Dr. Pavia for this honorable recognition and for his willingness to guide treatment for COVID-19 patients here in Utah and across the country. The guidelines are posted online (covid19treatmentguidelines.nih.gov) and will be updated often.